Home / Late annual reports / Eloxx Pharmaceuticals, Inc.
Filed 2025-04-01 路 Form NT 10-K 路 Accession 0001104659-25-030543 micro
Price before filing: n/a (n/a close, split/dividend-adjusted)
Market cap at flag: n/a 路 Latest: $88.5M (2026-10-16)
| Window | ELOX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | n/a | n/a | n/a | |
| 90 days | n/a | n/a | n/a | |
| 180 days | n/a | n/a | n/a |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
The company told the SEC it could not file its annual report on time (Form NT 10-K) and then missed the 15-day extension too. Late annual reports often precede restatements, auditor problems or going-concern warnings.
Status: filed late (report filed 2026-03-17)
Why this score: filed late on 2026-03-17; also within 90 days: Late quarterly report (NT 10-Q)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.